IP Library › Granted Patent US 8,158,653
Granted Patent B2
US 8,158,653 · App. 11/401,862 · Granted Apr 17, 2012

Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline

Assignee: Celgene Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,158,653
App. No.
11/401,862
Granted
Apr 17, 2012
Kind
B2
Abstract

Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal.

Claims (3)

1. An oral dosage form in the form of a capsule or a tablet comprising a therapeutically effective amount of compound of the formula:

or an acid addition salt thereof, and a pharmaceutically acceptable excipient.

2. The oral dosage form of claim 1 , wherein the compound is present at an amount of from 1 to 100 mg.

Continuity (5)
Division 10337602 · Jan 6, 2003
Continuation 09781179 · Feb 12, 2001
Continuation 09543809 · Apr 6, 2000
Division 09230389 · May 7, 1999
Related Publication 20060178402A1 · Aug 10, 2006